Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research & Development
Femme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
The purpose of this study is to compare Retosiban with Atosiban and show that retosiban is more effective in stopping spontaneous preterm labor and prolonges labor El fin del estudio es comparar retosibán con atosibán y demostrar que el atosibán es más efectivo en detener el parto pretérmino espontáneo y prolongar el parto
To demonstrate the superiority of retosiban to prolong pregnancy compared with atosiban Demostrar la superioridad de retosibán sobre atosibán para prolongar la gestación.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 months, on in-vivo macrophage activity, as assessed by FDG-PET/CT imaging, in the carotid arteries and aorta of subjects with established atherosclerosis
To measure in-vivo macrophage activity, by FDG-PET/CT imaging, in carotid arteries and aorta following a 12 week treatment with GW856553 (7.5 mg once daily and 7.5mg twice daily), in the setting of ch...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal allergies
The primary objective of this study was to demonstrate that FFNS provides superior nighttime symptom relief over fexofenadine.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III congestive heart failure
1. To determine the treatment effect across doses of GSK716155 relative to placebo on myocardial glucose uptake in patients with NYHA Class II/III heart failure over a 3 month period. 2. To determine ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
The INPACT study (Improving with Nadroparin the Prognosis in Advanced Cancer Treatment) A randomized, controlled trial to evaluate the effects of nadroparin on survival and disease progression in patients with advanced malignancies of the lung, pancreas, or prostate
The primary efficacy objective is to evaluate the effects of an intermittent schedule of nadroparin on death due to all causes in patients with advanced malignancies of the lung, pancreas, or prostate...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
Trial to evaluate the safety, tolerability and blood concentrations of multiple doses of GSK2269557 in COPD patients
Part A To assess the safety and tolerability of repeat doses of GSK2269557 administered as a dry powder to COPD patients. Part B To characterise the dose-response relationship of repeat doses of...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A 14 week study where each subject takes 3 medicines (each for 2 weeks) being developed to treat COPD
The primary objective of this study is to evaluate the lung function response following treatment with UMEC 125mcg, VI 25mcg, and UMEC/VI 125/25mcg administered once-daily via the Novel Dry Powder Inh...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A randomised, double-blind, placebo-controlled, 3-period cross-over study to evaluate the effect of two doses of GSK2190915 on the allergen-induced early asthmatic response in subjects with mild asthma
To evaluate the effect of treatment with repeat oral doses of GSK2190915 on the early asthmatic response (EAR) to inhaled allergen in mild asthmatic subjects compared with placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development
MAJ Il y a 4 ans
Study to evaluate the efficacy, safety and tolerability of combination dry powder Fluticasone Propionate and Salmeterol 250/50mcg in adults and adolescents with asthma
The primary objective of this study was to establish the noninferiority of the efficacy of FSC 250/50mcg ROTAHALER compared with FSC 250/50 mcg DISKUS BID in adults and adolescents with asthma.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
Study of a new drug’s effect on anemia in subjects with impaired kidney function who are on dialysis and a stable dose of rhEPO
Estimate the relationship between dose of GSK1278863 and hemoglobin (Hgb) response following switching from a stable dose of rhEPO in subjects undergoing HDD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
3
4
5
6
7
8
9
10
11
12
Suivant